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Abstract
 
We have established that the route of immunization with peptide-pulsed, activated DC leads to
memory CD8
 
 
 
 T cells with distinct distributions in lymphoid tissues, which determines the
ability to control tumors growing in different body sites. Both intravenous (i.v.) and subcutaneous
(s.c.) immunization induced memory T cells in spleen and control of metastatic-like lung tumors.
s.c. immunization also induced memory T cells in lymph nodes (LNs), imparting protection
against subcutaneously growing tumors. In contrast, i.v. immunization-induced memory was
restricted to spleen and failed to impart protective immunity against subcutaneously growing
 
tumors. Memory cell distribution and tumor control were both linked to injection route–
dependent localization of DCs in lymphoid compartments. Using peripheral LN–ablated mice,
these LNs were shown to be essential for control of subcutaneously growing tumors but not
lung metastases; in contrast, using immunized asplenic mice, we found that the spleen is necessary
and sufficient for control of lung tumors, but unnecessary for control of subcutaneously growing
tumors. These data demonstrate the existence of a previously undescribed population of
splenic-resident memory CD8 T cells that are essential for the control of lung metastases. Thus,
regional immunity based on memory T cell residence patterns is an important factor in DC-
based tumor immunotherapy.
Key words: active immunotherapy • regional immunity • vaccination • T cell memory • 
T cell homing
 
Introduction
 
DCs are potent antigen-presenting cells and are effective in
inducing both antiviral (1) and antitumor immune responses
in experimental animals (2) and humans (3). Immature DCs
in peripheral tissues have high phagocytic and macropi-
nocytotic activity, express a wide variety of receptors that
augment antigen uptake, and have low surface expression of
class I and II MHC and costimulatory molecules. Inflamma-
tory stimuli induce DC maturation, characterized by cessation
of phagocytosis and increased cell surface expression of class
I and II MHC molecules and costimulatory molecules (4, 5).
Maturing DCs down-regulate chemokine receptors associated
with tissue retention and simultaneously up-regulate CCR7
and CD62L, allowing them to migrate through the lym-
phatics to adjacent lymphoid tissue, where they present a
snapshot of recently acquired antigens to T cells (6, 7).
To interact with DCs, naive T cells enter LN and mucosal-
associated lymphoid tissue based on expression of specific
adhesion molecules and chemokine receptors (8). After the
immune response has subsided, subpopulations of central
memory cells have been defined that express adhesion
molecules that enable homing to either peripheral or intestinal
LN (9). However, regulation of T cell migration to spleen
and other LN compartments is not understood. An important
but unexplored issue is whether the localization of the primary
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Abbreviations used in this paper:
 
 AxLN, axillary LN; CFSE, 5-carboxyfluo-
rescein diacetate, succinimidyl ester; hTyrVac, recombinant vaccinia virus
encoding human tyrosinase; InLN, inguinal LN; MLN, mesenteric LN;
PulLN, pulmonary LN.T
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immune response in different lymphoid tissues is reflected
in the distribution of these central memory cells. Finally, it
should also be noted that these homing pathways have been
defined using CD4 T cells, and their relevance for CD8 T
cells is relatively unexplored.
DCs treated exogenously to express appropriate antigens
offer an important avenue for vaccination against tumors
(10–14). Antigen has been introduced into immature DC
by viral infection (15), RNA transfection (16), and incuba-
tion with apoptotic (17) or necrotic cells (18) or tumor ly-
sates (19), whereas synthetic peptides are most effective
when pulsed onto mature DCs (20). Such antigen-pulsed
DCs distribute in different lymphoid compartments when
injected into the body by different routes (11, 12, 21).
However, although these different distributions might be
expected to stimulate regionally localized T cell responses,
as yet there is no evidence in support of this possibility.
Recently, we described a model for evaluating immune
responses to a melanoma peptide antigen, tyrosinase
 
369–377
 
(Tyr
 
369
 
), using mice that express a recombinant human
HLA-A
 
*
 
0201 class I MHC molecule (2, 22). Expression of
tyrosinase protein in these mice leads to substantial but in-
complete tolerance to this epitope (22). However, the re-
sidual T cell population in tyrosinase-expressing animals
could be expanded to control melanoma outgrowth by im-
munization with Tyr
 
369
 
-pulsed DC (2). Using this model
in the present work, we have established that the route by
which DCs are introduced leads to differences in their dis-
tribution in lymphoid tissues. In turn, this determines the
location of the primary immune response, the distribution
of memory cells, and the ability to control the outgrowth
of tumors at different sites in the body.
 
Materials and Methods
 
Animals. 
 
Transgenic mice on the C57BL/6 background
expressing a chimeric MHC class I composed of the 
 
 
 
1 and 
 
 
 
2
domains of HLA-A
 
*
 
0201 and the 
 
 
 
3 domain of H2-D
 
d
 
 (AAD)
have been described previously (23). Mice with a radiation-
induced excision of the tyrosinase (
 
c
 
) coding locus on chromo-
some 7 (
 
c
 
38R145L
 
/
 
c
 
38R145L
 
; reference 24) were crossed onto
the C57BL/6-AAD background (albino AAD) as described
previously (22). Asplenic C57BL/6 Hox11
 
 
 
/
 
 
 
 mice (
 
Tlx
 
tmSjk
 
;
The Jackson Laboratory; reference 25) were crossed onto the
C57BL/6-AAD background. All animals were maintained in
pathogen-free facilities at the University of Virginia. All proto-
cols were consistent with accepted National Institutes of Health
guidelines for the care and use of laboratory animals and ap-
proved by the University of Virginia Institutional Animal Care
and Use committee.
 
Peptides. 
 
Synthetic peptides were made by standard Fmoc
chemistry using a peptide synthesizer (model AMS422; Gilson
Co. Inc.) and purified to 
 
 
 
98% purity by reverse-phase HPLC
on a C-8 column (Vydac). Purity and identity were confirmed
using a triple quadrupole mass spectrometer (Finnigan).
 
Cell Lines. 
 
B16-F1 (CRL-6323) was obtained from the
American Type Culture Collection and maintained in RPMI
1640 (Mediatech) supplemented with 5% FBS (Sigma-Aldrich)
and SexXtend (Irvine Scientific). B16-F1 was transfected with a
plasmid containing the genes for AAD and G418 resistance under
 
the control of the class I promoter, as described previously (2),
and the resultant cell line is referred to as B16-AAD. B16-AAD
cells were 
 
 
 
98% AAD positive and expressed AAD stably for at
least 6 wk in the absence of G418.
 
DC Culture. 
 
DCs were generated by culturing mouse bone
marrow cells in GM-CSF and IL-4 (BD Biosciences), as de-
scribed previously (26), and activated by overnight culture with
an equal number of irradiated (3,000 rads) NIH-3T3 cells trans-
fected to express CD40L (gift of R. Lapoint, University of Mon-
treal, Quebec, Canada). The resulting activated DCs were
CD80
 
hi
 
CD86
 
hi
 
, and 
 
 
 
85% expressed IL-12 by intracellular stain-
ing (unpublished data). DC expression of CD62L was assessed by
flow cytometry using anti-CD62L mAb (BD Biosciences).
CCR7 expression was determined by flow cytometry using
ELC-19 fusion protein (gift of U. von Andrian, Harvard Univer-
sity, Cambridge, MA) and anti–human IgG mAb (Jackson Im-
munoResearch Laboratories).
 
Immunization. 
 
CD40L-activated DCs were pulsed with the
indicated concentration of peptide for 4 h at 37
 
 
 
C in HBSS con-
taining 5% FBS and 5 
 
 
 
g/ml human 
 
 
 
2
 
-microglobulin (Calbio-
chem). In all experiments, an altered ligand of Tyr
 
369
 
 (Tyr
 
369
 
Y,
YMDGTMSQV) was used as the immunogen, as described pre-
viously (2). The HLA-A
 
*
 
0201–restricted epitope of the influenza
M1 protein (GILGFVFTL) was used as an irrelevant control pep-
tide. Cells were washed twice, resuspended in physiologic saline,
and 100 
 
 
 
l of cell suspension injected by the s.c. route into the
scapular fold or flank, as indicated, or i.v. into the dorsal tail vein.
Unless indicated otherwise, mice received 10
 
5
 
 DCs. For analysis
of recall responses, DC-immunized mice were injected i.v. with
10
 
7
 
 PFU of hTyrVac, a recombinant vaccinia virus encoding hu-
man tyrosinase.
 
Tumor Induction and Measurements. 
 
Subcutaneous tumors
were established by injection of 4 
 
 
 
 10
 
5
 
 B16-AAD in 200 
 
 
 
l of
physiologic saline. Lung metastases were induced by tail vein in-
jection of 4 
 
 
 
 10
 
5
 
 B16-AAD in 200 
 
 
 
l of physiologic saline.
Tumor cells were 100% viable by trypan blue exclusion (unpub-
lished data). Mice were evaluated for subcutaneoulsy growing
tumor by palpation, and 100% of B16-AAD–challenged naive
tyrosinase
 
 
 
 animals developed palpable tumors by day 10. Tu-
mor growth was measured at 
 
 
 
72 h intervals using a vernier
caliper, as described previously (2). Mice challenged with tumor
i.v. were killed on day 21 after the injection, and surface lung
metastatic lesions enumerated using a 40 magnification dissect-
ing scope with the aid of an eyepiece grid. All analyses were
performed in a blinded manner.
 
Tumor Resection and Evaluation of Infiltrating Lymphocytes.
 
Subcutaneous tumors were resected, digested in 0.5% collage-
nase D (Roche Diagnostics) for 45 min, and homogenized. The
suspension was filtered through nylon, and then debris and dead
cells were separated on a Ficoll-Paque gradient (Amersham Bio-
sciences). Lymphocytes were separated on a Lympholyte-M gra-
dient (Accurate Chemical). Antigen-specific CD8
 
 
 
 T cells were
enumerated using HLA-A
 
*
 
0201–Tyr
 
369
 
Y tetramers (National
Institute of Allergies and Infectious Diseases Tetramer Core Fa-
cility) at 1:100 dilution. Cells were costained with anti-CD8 and
anti–TCR-
 
 
 
 chain (BD Biosciences) at 1:1,000 dilution and an-
alyzed by flow cytometry.
 
DC Tracking Studies. 
 
To determine lymphoid distribution of
DC after injection, CD40L-activated DCs were labeled with
5-carboxyfluorescein diacetate, succinimidyl ester) (CFSE; Mo-
lecular Probes) and injected (10
 
5
 
 cells) s.c. or i.v. At various times
after injection, lymphoid cells from spleen and LN were collected
and stained with anti-CD11c (BD Biosciences). The number ofT
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infiltrating DC (CD11c
 
 
 
CFSE
 
hi
 
 cells) was quantitated by flow
cytometry.
 
LN Ablation. 
 
Albino AAD mice devoid of peripheral LN
were generated using soluble lymphotoxin 
 
 
 
 receptor Ig as de-
scribed previously (27). Peripheral LN depletion was confirmed at
the termination of each experiment. LN ablation was scored posi-
tive when axillary, brachial, inguinal, and popliteal LN could not
be visually detected by inspection at 100
 
 
 
 magnification after s.c.
injection with Lymphazurin 1% tracking dye (Ben Venue Labs).
 
Ex Vivo Analysis of Antigen-specific T Cells. 
 
CD8
 
 
 
 T cells
were enriched from spleens and LN of naive and immunized
mice using a StemSep column (StemCell Technologies, Inc.) ac-
cording to the manufacturer’s instructions. Preparations were
consistently 85–95% CD8
 
 
 
 as assessed by flow cytometry. En-
riched CD8
 
 
 
 T cells were directly assessed for cytokine produc-
tion using target/stimulator cells that had been pulsed overnight
with 100 
 
 
 
M of peptide. Peptide-pulsed stimulator cells were in-
cubated with CD8
 
 
 
 T cells for 5 h at a ratio of 1:1 in medium
supplemented with 50 U/ml IL-2 (Chiron Corp.) and 10 
 
 
 
g/ml
Brefeldin A (Sigma-Aldrich). Stimulated cells were stained with
PE-conjugated anti-CD8 (BD Biosciences), washed, fixed, and
permeabilized in Cytofix/Cytoperm (BD Biosciences), further
stained with FITC-conjugated anti-IFN
 
 
 
 (BD Biosciences) or
isotype-matched controls, and analyzed by flow cytometry. Anti-
gen-specific cells were also enumerated using HLA-A
 
*
 
0201-
Tyr
 
369
 
Y tetramers.
 
Statistics. 
 
Statistical comparisons were performed using Stu-
dent’s 
 
t
 
 test; survival was plotted using Kaplan-Meier curves and
statistical relevance was determined using log-rank comparison.
Unless noted, data are presented as means 
 
 
 
 SD of pooled data
from four to six independent experiments.
 
Online Supplemental Material. 
 
Fig. S1 shows three indepen-
dent tumor outgrowth experiments in which mice expressing a
recombinant class I MHC molecule (AAD) were immunized
once with 10
 
5
 
 DCs and challenged 21 d later with 4 
 
 
 
 10
 
5
 
 s.c.
injected B16-AAD melanoma. DCs were unpulsed or pulsed
with 1 
 
 
 
M of either Tyr
 
369
 
Y or influenza A M1 peptide. Data in
each group are mean of five separate animals 
 
 
 
 SD. Online sup-
Figure 1. s.c., but not i.v., immunization with peptide-
pulsed DCs controls s.c. melanoma outgrowth. Mice
were immunized once with unpulsed or 1  M peptide-
pulsed DCs, and B16-AAD melanoma was injected s.c.
21 d later. (A) Kinetics of tumor outgrowth after i.v. or
s.c. immunization with 105 DCs pulsed with either
Tyr369Y or a peptide corresponding to residues 57–66
of the influenza A M1 protein. Data are the mean of
five separate animals   SD; representative data from
one of six similar experiments are shown. Additional
representative experiments are shown in Fig. S1. (B)
Kaplan-Meier survival curves after B16-AAD challenge
in mice immunized i.v. or s.c. with 105 DCs pulsed
with Tyr369Y- or M1 flu peptide-pulsed DCs, scored as
days from challenge until tumor diameter exceeds 300
mm2. Survival was significantly increased in s.c. immu-
nized animals compared with untreated (P   0.001).
Data are for groups of five animals; representative data
from one of six similar experiments are shown. (C)
Day 21 s.c. tumor size in mice immunized i.v. or s.c.
with 103 to 5   105 DCs pulsed with Tyr369Y (1  M).
P-values indicate statistical significance compared
with unimmunized control (black bar) by two-sample
Student’s t test.T
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plemental material is available at http://www.jem.org/cgi/
content/full/jem.20021348/DC1.
 
Results
 
Intravenous Immunization with Peptide-pulsed DC Fails to
Control Subcutaneous Melanoma Outgrowth. 
 
Mice express-
ing a recombinant class I MHC molecule (AAD) were im-
munized with CD40L-activated and tyrosinase peptide
(Tyr
 
369
 
Y)–pulsed DCs by either the s.c. or i.v. route. 3 wk
later, mice were challenged with a s.c. bolus of B16-AAD
melanoma cells. In six experiments involving five animals
in each group (representative experiments shown in Fig.
1 A and Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20021348/DC1), measurable outgrowth
was delayed by 8.7 
 
 
 
 1.5 d in mice immunized s.c. with
Tyr
 
369
 
Y-pulsed DCs, compared with unimmunized litter-
mates (P 
 
 
 
 0.005). Survival, defined as the time point
when tumors achieved or exceeded 300 mm
 
2
 
, was also sig-
nificantly (P 
 
 
 
 0.001) enhanced by a mean of 22.3 
 
 
 
 2.4 d
in the same experiments (one representative experiment is
shown in Fig. 1 B). Surprisingly, tumor outgrowth was not
delayed in animals immunized i.v. with the same DCs and
no survival advantage was conferred, although this immu-
nization has been shown previously to induce a significant
antigen-specific CD8
 
 
 
 T cell response in spleen (20). s.c.
immunization with unpulsed DCs or DCs pulsed with in-
fluenza M1 peptide did not delay tumor outgrowth or en-
hance survival, establishing that a tumor antigen-specific
immune response was required. In these experiments, 10
 
5
 
DCs were injected; however, no control of outgrowth of
subcutaneously growing tumors was observed in mice im-
munized i.v. with numbers of Tyr
 
369
 
Y-pulsed DCs ranging
between 10
 
3
 
 and 5 
 
 
 
 10
 
5
 
 per animal (Fig. 1 C). In contrast,
as few as 10
 
4
 
 DCs injected by the s.c. route were sufficient
for maximal control (Fig. 1 C). These data demonstrate
that the immunization with DCs via the i.v. route fails to
induce an immune response capable of controlling subcuta-
neously growing melanomas.
To further investigate the failure of i.v. immunization
with DCs to control subcutaneously growing tumors,
we used HLA-A
 
*
 
0201-Tyr369Y tetramers to enumerate
Tyr369Y-specific CD8  T cells infiltrating tumors that had
achieved comparable sizes in s.c. or i.v. immunized mice. A
substantial population of Tyr369Y-specific CD8  cells was
recovered from 150 mm2 tumors growing in s.c. immu-
nized mice (Fig. 2 A). In contrast, there was no significant
infiltration of antigen-specific T cells in tumors of equiva-
lent size from i.v. immunized animals (Fig. 2 B). Similar
data were obtained when tumors of different sizes, obtained
at different points during their outgrowth, were compared
(Fig. 2 C). Although tumors from i.v. immunized animals
achieved a given size at an earlier time relative to those from
s.c. immunized mice, infiltration of 100-mm2 tumors ob-
tained from s.c. immunized mice on day 15 was still sub-
stantially greater than that of 150-mm2 tumors from i.v. im-
munized mice obtained on the same day. These data suggest
that either the memory T cells primed by i.v. immunization
are not reactivated by a subcutaneously growing tumor, or
that they are activated but do not infiltrate the tumor.
Figure 2. Antigen-specific CTL infiltrate subcutaneously growing
tumors only after s.c. delivery of immunizing DCs. Melanomas
from naive or DC-immunized tumor-challenged mice were ana-
lyzed for infiltrating Tyr369Y-specific CD8  lymphocytes using
HLA-A*0201  Tyr369Y tetramers. (A) Infiltration of 150 mm2
subcutaneously growing B16-AAD tumor from s.c. immunized
mouse. (B) Infiltration of 150 mm2 s.c. growing B16-AAD tumor
from i.v. immunized mouse. (C) Infiltration of CD8  tetramer 
cells into tumors of 100, 150, or 250 mm2. P-values indicate statistical
significance compared with s.c. immunized animals (gray bar), in
the same time point grouping, by two-sample Student’s t test.T
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I.v. Immunization with Peptide-pulsed DCs Enables Control
of Metastatic-like Lung Melanomas.  We showed previously
that i.v. immunization with Tyr369Y-pulsed DCs induced
an antigen-specific CD8  response in spleen (26). To de-
termine whether these T cells were functional in control-
ling tumors growing in other body sites, we evaluated the
ability of mice immunized with DCs via the i.v. route to
control metastatic-like lung tumors (Fig. 3). i.v. immuniza-
tion with 105 Tyr369Y-pulsed DCs resulted in a 70   9.3%
reduction in the number of lung lesions 21 d after chal-
lenge, as compared with the number in untreated control
mice. s.c. immunization with the same number of DCs also
led to a significant decrease in the number of lungs lesions
(29    9.1%). In contrast to results with subcutaneously
growing tumors shown in Fig. 1 C, control of lung tumor
metastases correlated (logarithmic r2    0.993) with the
number of DCs used for immunization over the entire
range of 103 to 5   105 per animal, regardless of delivery
route. The ability of T cells induced by i.v. immunization
to control lung metastatic lesions demonstrates they were
tumor-reactive and not functionally compromised, and
suggests that their failure to control subcutaneously grow-
ing B16-AAD was due either to an inability of memory T
cells to be reactivated by subcutaneously growing tumors,
or to an inability of reactivated effector cells to localize sub-
cutaneously. Because DCs from subcutaneously growing
tumors have been shown to migrate to regional draining
LN (28), we favored the first interpretation and hypothe-
sized that DCs introduced via different routes would mi-
grate to distinct lymphoid compartments and only stimulate
the production of memory T cells at those sites.
Tumor Control Correlates with Distribution of DCs in Sec-
ondary Lymphoid Tissues after s.c. and i.v. Immunization.
To determine whether the immunization route dictates
the lymphoid compartment distribution of DCs, 105
CD40L-activated DCs were labeled with CFSE, injected
either s.c. or i.v., and their location assessed at various
times by gating on both CFSEhi and CD11c  events in
cell suspensions isolated from LN and spleen. The level of
CFSE fluorescence was equivalent in CD11c  cells before
transfer (Fig. 4 A) and after recovery from spleen (Fig.
4 B) and LN (not depicted). Furthermore, all recovered
CFSEhi cells were also CD11c  (Fig. 4 C), establishing
that the cells identified were unlikely to be endogenous
DC or macrophages that acquired CFSE from the adop-
tively transferred population. After injection via the s.c.
route, DCs were detected in the axillary LN (AxLN)
draining the injection site and in spleen (Fig. 4 D). How-
Figure 3. Metastatic-like lung lesions are controlled by i.v. immunization
and partially controlled by s.c. immunization with peptide-pulsed DCs.
Mice were immunized with the indicated number of 1  M Tyr369Y-
pulsed DCs, delivered either s.c. or i.v., and B16-AAD melanoma was
injected i.v. 21 d later. Surface lesions were enumerated 21 d after tumor
inoculation. P-values indicate statistical significance compared with un-
immunized control animals (black bar) by two-sample Student’s t test.
Figure 4. Phenotype and distribution of
CD40L-activated DCs after s.c. and i.v. injec-
tion. CD40L-activated DCs were labeled with
CFSE, adoptively transferred, and recovered
from the indicated lymphoid organs at the indi-
cated times. (A) Fluorescence of CFSE-stained
(shaded histogram) and unstained (white histo-
gram) CD40L-activated DCs before injection.
(B) CD11c staining and CFSE staining of gated
CD11c  cells recovered from spleen 24 h after
injection. (C) CFSE and CD11c staining of total
spleen cells, excluding red blood cells and debris,
recovered 24 h after injection. (D) Total
CD11c CFSE  cells in various lymphoid com-
partments 4 h after injection of 105 CFSE-labeled
CD40L-activated DCs either s.c. in the scapular
region or i.v. (E) CD62L expression on CD40L-
activated DC (black histogram), splenic CD8 
T cells (dark gray histogram), unstained DCs
(light gray histogram), and isotype-control
stained DCs (white histogram). (F) CCR7
expression on CD40L-activated DCs (shaded
histogram) and splenocytes (white histogram).T
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ever, no DCs were observed in inguinal LN (InLN) and
popliteal LN, both of which drain skin but are outside the
drainage of the injection site (Fig. 4 D and not depicted).
In addition, DCs were not observed in either mesenteric
LN (MLN) or pulmonary LN (Fig. 4 D, PulLN) at any
time up to 72 h after the injection (Table I). The failure to
find these DCs in LN other than those draining the injec-
tion site was surprising because they expressed both
CD62L (Fig. 4 E) and CCR7 (Fig. 4 F). However, the
level of CD62L was only 20% as much as that expressed on
splenic T cells. Similar low levels on B and T lymphocytes
have been associated with a failure to migrate into periph-
eral LN (29). Interestingly, the number of s.c. injected DCs
in the AxLN was substantially smaller ( 3,000 cells in sev-
eral experiments) than in the spleen ( 16,000), and
whereas the number of DCs in AxLN remained constant
when up to 5   105 DC were injected, the number of DCs
in spleen directly correlated with the number injected (un-
published data). These data suggest that the number of DCs
injected was significantly greater than the holding capacity
of the draining LN, and that the excess DCs migrated via
the blood, but not lymphatics, to the spleen.
As expected, DCs injected via the i.v. route were found
in large numbers in the spleen (approximately twice as
many as had been observed after s.c. injection). However,
i.v. injected DCs were never detected in any LN compart-
ment examined (Fig. 4 D), including skin-draining LN,
MLN, and PulLN, even though these cells express both
CD62L and CCR7. Nonetheless, these data demonstrate
that CD40L-activated DCs injected via the i.v. route fail to
access LN compartments, but show enhanced representa-
tion in the spleen.
DC Distribution in Secondary Lymphoid Tissue Determines
the Sites of Antigen-specific T Cell Expansion.  The afore-
mentioned results established a direct correlation between
the presence of immunizing DCs in LN and protection
against melanoma growing in a s.c. site, and between the
Table I. Quantitation of CFSE  CD11c  DC in LN and Spleen 
after Injection of 105 Cells
Time after
injection
i.v.-injected DCa s.c.-injected DCa
Spleen Axillary LN Spleen Axillary LN
h
4 26.2   1.6  0.1 15.9   1.2 3.0   0.2
24 9.4   1.4b  0.1 7.4   0.5c 0.76   0.02b
72 2.8 ± 0.3b  0.1 2.3   0.5b 0.26   0.09b
Data represent mean   SD for three mice.
aPercentage of injected cells.
bP   0.005 compared with 4-hr time point for the same injection route
and lymphoid organ.
cP   0.05 compared with 4-hr time point for the same injection route
and lymphoid organ.
Figure 5. Immunization route
influences the location of DC-
induced antigen-specific T cell
expansion. Mice were immunized
with 1  M 105 Tyr369Y-pulsed
DCs, delivered either s.c. or i.v.
7 d later, spleen and LNs were
evaluated for total Tyr369Y-specific
CD8  T cells using either (A)
HLA-A*0201–Tyr369Y tetramers
or (B) intracellular production of
IFN-  by CD8  T cells after
stimulation with peptide-pulsed
targets. Numbers in dotplots rep-
resent the percentage of CD8 
tetramer  events (A) or CD8 
IFN-   events (B) in the total
lymphocyte population of the
indicated lymphoid compart-
ment. (C) Total tetramer  and
IFN-   CD8  cells are shown
in each compartment.T
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number of immunizing DCs present in spleen and the ex-
tent to which melanoma growing in the lungs was con-
trolled. This suggested the hypothesis that the presence of
DCs defines the secondary lymphoid compartments in
which antigen-specific T cells are activated or expanded.
To evaluate this possibility, we determined the peak mag-
nitude of the primary antigen-specific T cell responses in
different lymphoid compartments 7 d after s.c. or i.v. im-
munization with peptide-pulsed DCs. Tyr369Y-specific
CD8  cells were quantified in different LN subsets and in
spleen by surface staining with HLA-A2-Tyr369Y tetramer
(Fig. 5 A) and by measuring antigen-induced intracellular
IFN-  accumulation (Fig. 5 B). After s.c. immunization,
comparable numbers of antigen-specific CD8  T cells
were detected in the draining AxLN and the spleen (Fig.
5 C). However, no significant response was detected in dis-
tal skin-draining InLN, nor in MLN or PulLN. In contrast,
i.v. immunization with DCs induced approximately twice
as many antigen-specific CD8  T cells in the spleen as did
s.c. immunization (Fig. 5 C). However, i.v. immunization
failed to induce any significant antigen-specific primary re-
sponses in any LN examined. Thus, the size and location of
primary CD8  T cell responses on day 7 after immuniza-
tion correlated directly with the distribution of DCs ob-
served shortly after injection, as well as with the ability to
control subsequent tumor outgrowth 2–3 wk later.
DC Immunization by Different Routes Induces Distinct
Populations of Memory T Cells That Reside in Either LN or
Spleen.  Despite the localization of primary T cell re-
sponses shown in the previous section, control of tumor
outgrowth in the protective immunization model used
here depends on the distribution and/or reactivation of
memory cells. Attempts to quantify the apparently small
number of AAD  Tyr369-specific memory cells in LN and
spleen from mice bearing subcutaneouay growing B16-
AAD tumors using MHC tetramers or antigen-induced
IFN-  accumulation were unsuccessful (unpublished data).
Consequently, we determined the location of memory T
cells induced by DC immunization by examining recall re-
sponses to recombinant vaccinia virus encoding human ty-
rosinase (hTyrVac). In contrast to DCs, hTyrVac induced
equivalent antigen-specific primary responses in spleen and
multiple LN after i.v. injection (Fig. 6 A). Although pri-
mary responses to hTyrVac in naive animals were maximal
at day 7, they remained minimal on day 4. Thus, by evalu-
ating AAD Tyr369Y-specific T cells on day 4 after hTyr-
Vac challenge in animals that had been immunized previ-
ously with Tyr369Y-pulsed DCs, we visualized only the
response of the memory cells.
In animals immunized with DCs via the s.c. route, recall
responses were robust in draining AxLN and spleen, in
keeping with the location of the peak primary T cell re-
sponse (Fig. 6 B). Significant recall responses were also ob-
served in peripheral LN residing in draining beds not tar-
geted by the scapular-region s.c. immunization (InLN and
popliteal LN), and in which no DC infiltration or primary T
cell response had been seen (Fig. 6 B and not depicted).
However, these responses were invariably lower than those
observed in AxLN. Unexpectedly, recall responses were also
noted in MLN and PulLN, although again these responses
Figure 6. Recall responses are
enriched in the compartments
where primary responses are
observed.  (A) Antigen-specific
hTyrVac-induced primary re-
sponses at days 4 and 7, measured
as intracellular accumulation of
IFN-  by CD8  T cells incu-
bated with peptide-pulsed targets.
(B) Antigen-specific hTyrVac-
induced recall responses in mice
immunized previously (21 d)
with 1  M 105 Tyr369Y-pulsed
DCs. Tyr369Y-specific responses
were measured by costaining with
anti-CD8 and HLA-A*0201–
Tyr369Y tetramers, and by assessing
intracellular accumulation of IFN- 
by CD8  T cells incubated with
peptide-pulsed targets.T
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were of lower magnitude than in InLN and popliteal LN. In
animals immunized with DCs via the i.v. route, memory re-
sponses were observed exclusively in spleen, demonstrating
that memory T cells resulting from a primary response con-
fined to the spleen do not migrate to major LN compart-
ment subsets. Based on this result, the CD8  memory T
cells observed in peripheral and mucosal LN in distinct
drainages after a primary response in the AxLN most likely
arise from cells that leave the AxLN and circulate.
LN Memory T Cells Are Necessary and Sufficient for Control
of Subcutaneously Growing Tumors, Whereas Spleen-resident
Memory T Cells Are Necessary and Sufficient for Control of
Lung Metastatic-like Lesions.  The results in the previous
section suggested that Tyr369Y-specific memory cells in
skin-draining LN and spleen enable, respectively, the con-
trol of tumors growing either subcutaneously or in the
lungs. To directly define the requirement for peripheral
LN in controlling tumor outgrowth, we used mice whose
peripheral LN had been ablated by perinatal administration
of lymphotoxin   receptor immunoglobulin Ig fusion pro-
tein (27). Both mucosal LN and the splenic compartments
in these mice are normal (27 and unpublished data). These
experiments were performed in AAD  albino mice instead
of AAD  tyrosinase  mice because their lack of tolerance
to tyrosinase (22) enables AAD  albino mice to control
B16-AAD outgrowth without prior immunization (2). Pe-
ripheral LN–ablated AAD  albino mice and intact mice
controlled B16-AAD lung metastatic lesions comparably,
and substantially better than did intact AAD  tyrosinase 
mice (Fig. 7 A). However, the ability of peripheral LN–
ablated AAD  albino mice to control subcutaneously
growing B16-AAD was substantially diminished compared
with that of intact mice, and was only marginally better
than that of AAD  tyrosinase  mice (Fig. 7 B). Thus, the
absence of peripheral LN resulted in a selective failure to
control the outgrowth of subcutaneously growing tumors.
To directly define the requirement for spleen-resident
memory T cells in controlling tumor outgrowth, we used
Figure 7. Peripheral LNs and
spleen, respectively, are necessary
and sufficient to control the out-
growth of s.c. and lung metastatic-
like tumors. (A) Tumor out-
growth at day 21 after B16-AAD
challenge of intact tyrosinase 
and albino mice and LN-ablated
albino mice. P-values indicate
statistical significance compared
with intact tyrosinase  animals
(black bar) by two-sample Stu-
dent’s t test. (B) Outgrowth of
s.c. melanoma in AAD  normal
or asplenic (Hox11 / ) mice
immunized previously with
peptide-pulsed DCs, either i.v.
or s.c. Data are mean   SD for
five animals. (C) Day 21 out-
growth of subcutaneously growing
melanomas and lung metastatic-
like lesions in immunized and
naive AAD  and AAD Hox11 / 
mice. Data are mean   SD for
10 pooled animals from two in-
dependent experiments.T
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asplenic AAD Hox11 /  mice (25). These mice were
tyrosinase  and, therefore, partially tolerant, so we evalu-
ated tumor outgrowth in both naive and immunized ani-
mals. After s.c. immunization, AAD Hox11 /  mice and
AAD  mice with normal spleens both controlled subcuta-
neously growing B16-AAD to a similar extent (Fig. 7, B
and C). Together with the LN ablation results, this lack of
dependence on the spleen further emphasizes the impor-
tance of LN-resident immunity in controlling the out-
growth of subcutaneously growing tumors. In contrast, re-
gardless of the route of immunization, AAD Hox11 / 
mice were incapable of controlling B16-AAD outgrowth
in lung (Fig. 7 C). Thus, the absence of spleen-resident T
cells resulted in a selective failure to control the outgrowth
of tumors in lung, establishing both the necessity and suffi-
ciency of the spleen to mediate immunity against tumors
growing in the lungs.
Discussion
In the present paper, we have established that the loca-
tion of primary T cell activation, the distribution of mem-
ory T cells, and control of localized tumor outgrowth are
determined by the route of immunization with tumor anti-
gen-pulsed DCs. After s.c. injection, a small number of
DCs apparently saturate draining LN and the remainder
enter the spleen, but not noncontiguous LN beds. Subse-
quent antigen-specific primary CD8  T cell responses are
limited to the lymphoid compartments in which DCs lo-
calize, whereas memory cells redistribute to LN outside the
draining node bed of the immunization site. In contrast,
i.v. injected DCs enter only spleen, leading to primary and
memory CD8  T cells that are present in the spleen, but
absent from major LN compartments. This demonstrates
that memory CD8  T cell distributions, which presumably
reflect their homing characteristics, are defined by the
compartment (LN or spleen) in which the initial APC–T
cell interactions occur. In keeping with this, we also
showed that peripheral LNs are necessary and sufficient for
control of subcutaneously growing tumors. Conversely,
spleen-resident memory T cell immunity is required for
control of tumor growing as metastatic-like lung lesions,
but spleen is not necessary for the induction or mainte-
nance of effective antitumor T cells in peripheral LN. Col-
lectively, these data demonstrate a correlation between the
presence of antigen-specific memory T cells in lymphoid
compartments that are directly accessible to tumor cells or
to DC-presenting tumor antigens, and the capacity to con-
trol tumor outgrowth. These results illustrate fundamental
processes of T cell localization that are important for im-
munologic control of tumors growing in different sites in
the body, and also demonstrate the critical nature of the
immunization route when DCs are used as immunothera-
peutic adjuvants.
Some previous work has examined, in a more prelimi-
nary way, the impact of DC immunization via different
routes on either immune responses or antitumor efficacy.
Lambert et al. (19) compared i.v., s.c., and intranodal im-
munization and concluded that intranodal immunization
was superior for the induction of antitumor immunity.
However, only lung metastases were examined in this pa-
per, and consequently there was no evaluation of differ-
ences in immunity to tumors growing in different sites.
There was also no examination of DC migration patterns
or the location of memory responses. This work did show
that tumor control was comparable after immunization via
s.c. and i.v. routes, whereas in our work, the s.c. route was
somewhat less effective. However, paradoxically, this
work also showed that the number of antigen-specific T
cells recovered from spleen was lower after s.c. than i.v.
immunization. Our results demonstrate a direct relation-
ship between the number of DCs infiltrating the spleen
(depending, in turn, on immunization route), the size of
the primary and memory responses, and control of lung
tumor outgrowth. In a similar vein, Eggert et al. (11) and
Okada et al. (12) compared s.c. and i.v. immunization
with DCs, but only evaluated subcutaneously implanted
tumors. As we have demonstrated, both of these groups
showed that i.v. immunization failed to control outgrowth
of tumor in s.c. compartments. However, neither of these
papers examined control of tumors growing in different
sites nor lymphoid distribution of antigen-specific T cells.
Instead, both groups reported that i.v. immunization failed
to induce any immune response in the spleen at all. This
was despite the demonstration by Eggert et al. (11) of a
significant number of DCs in this organ. Thus, we have
reached an entirely different conclusion from these previ-
ous works. We find that i.v. injection of DCs is not a defi-
cient route of immunization, but rather that it induces
large responses in the spleen, and that these responses are
effective in controlling lung metastases. Finally, Fong et al.
(13) reported that intradermal and intralymphatic injection
of peptide-pulsed PBMC-derived DCs led to antigen-spe-
cific immune responses in melanoma patients, whereas i.v.
immunization did not. However, this work did not evalu-
ate DC migration, or the existence and location of Ag-
specific T cells in any organs except blood, and there was
no examination of the ability of these immunizations to
control tumors. In contrast to our work and the papers
cited herein, Zitvogel et al. (30) has demonstrated that i.v.
immunization with DCs results in effective control of s.c.
or intradermal tumors (30). However, these analyses used
repetitive immunization with large numbers of relatively
immature DCs over a short time interval. DC migration
was not evaluated, nor was there any evaluation of primary
and memory T cell responses in skin-draining LNs. Nei-
ther of these analyses used B16, which may be relevant to
the ability of tumors to initiate an immune response in lo-
cal versus distal lymphoid compartments. Collectively, no
previous work has suggested the existence of regionally
distinct immune responses, nor examined control of tu-
mors growing in different sites in the body. The present
paper is the first comprehensive evaluation of the impact
of DC immunization route on localization of primary and
memory T cell responses and subsequent control of tumor
outgrowth, and the first to demonstrate differences in theT
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effectiveness of local immunity against tumors growing in
different sites.
A central observation in the present work is that i.v. in-
jection of DCs induces primary activated and memory T
cells that are localized in spleen, but absent from major LN
subsets. This contrasts strongly with the systemic immunity
in both spleen and several different noncontiguous LNs in-
duced by injection of vaccinia virus via the same route. Al-
though it is formally possible that virus introduced i.v.
could be cleared in the spleen but lead to the activation of
DCs or T cells that circulate systemically, we favor the hy-
pothesis that the virus itself disseminates widely throughout
the body, activating discreet populations of primary and
memory T cells in different lymphoid compartments. Pre-
vious work has established that memory T cells differen-
tially express CD62L and  4 7 integrin, and that these
molecules enable extravasation into peripheral LNs or into
intestinal LNs and lymphoid tissue, respectively (31). How-
ever, the factors that might control any selective extravasa-
tion process into the white pulp of the spleen (as well as
PulLN) remain undefined (32). Our results also demon-
strated that s.c. injection of DCs led specifically to primary
T cell responses in draining LN, and memory responses in
both noncontiguous peripheral LN and mucosal LN. These
results suggest that DCs in peripheral LNs stimulate the de-
velopment of CD8  memory T cells that circulate indis-
criminately among different LN compartments. Based on
previous work (31), we had expected that CD8  central
memory cells induced in the AxLN by s.c. injected DCs
would have accessed only cutaneous-draining LNs. It is
unclear whether our results reflect a difference in the hom-
ing of memory CD8  cells induced by our immunization
protocol, or whether small populations of memory cells
arise from cells that rapidly migrate into these LN before
expression of tissue-specific receptors. Nonetheless, our
data demonstrate that memory cell localization is defined
by the immunologic compartment in which the initial
APC–T cell interaction occurs and point to the existence
of a distinct population of memory CD8  T cells that are
selectively resident in the spleen. Further analysis of the
homing characteristics and receptors expressed on these T
cells is clearly warranted.
Recent work has highlighted the existence of effector
memory T cells that persist in an activated state in nonlym-
phoid tissue, in addition to the central memory T cells that
remain in lymphoid organs after the immune response has
subsided (33, 34). Our model system does not provide suf-
ficient sensitivity to directly examine the existence and lo-
cation of effector memory T cells after immunization with
DCs via different routes. Thus, it is possible that i.v. immu-
nization with peptide-pulsed DCs induces a population of
lung-resident effector memory cells that participate in the
control of subsequent tumor outgrowth. Nonetheless, our
results establish that control of lung metastatic-like lesions is
directly correlated with the number of antigen-specific re-
call T cells in the spleen, which are presumably differenti-
ated from local central memory cells, and absence of spleen
precludes protective immunization using peptide-pulsed
DC. In addition, control is apparently not enhanced by the
presence of memory cells in PulLNs. Similarly, the essential
role of peripheral LNs in the control of s.c. tumor in unim-
munized albino mice cannot be attributed to effector
memory cells, although this may differ in immunized
tyrosinase  mice. Thus, the role of effector memory in
controlling tumor outgrowth, while not formally excluded,
seems to have limited significance in this model. At the
least, the distribution of central memory cells in peripheral
LNs and spleen may serve as a proxy for the distribution
and magnitude of effector memory cells.
These considerations highlight an additional uncertainty
in understanding why memory T cells induced by i.v. im-
munization fail to control the outgrowth of subcutaneous
tumors. It is possible that T cells activated in spleen are in-
capable of infiltrating cutaneous sites, a limitation that
would presumably apply to both effector and effector
memory T cells. Alternatively, antigen from subcutane-
ously growing tumors may not reach the spleen, such that
activation of splenic T cells fails to occur. Although we
have shown that excess s.c. injected DCs migrate to the
spleen, the number that infiltrate tumors and subsequently
migrate to regional LNs is almost certainly lower than the
number we inject. Indeed, it has been demonstrated that
antigens captured in the skin are presented by DCs exclu-
sively in the draining LNs, and skin-derived antigens are
found in spleen only in the absence of LNs (35). Tumor-
induced DC dysfunction may further limit the number of
activated tumor antigen-bearing DCs that exit the tumors,
as many tumors release immunosuppressive factors and
chemokines that interfere with DC activation and matura-
tion (36). Further work is required to distinguish between
these two possibilities.
Our work demonstrates that CD8  T cell memory in-
duced in a peripheral LN drainage bed leads to the seeding
of memory cells in distinct LN beds, even though these
compartments were devoid of injected DCs or Ag-specific
CD8  primary immune responders. Our data show that
primary responses in LN occur only in the draining node,
and, therefore, involve only a small number of both DCs
and responding T cells. However, from the point of view
of immunotherapy, distribution of T cell memory through-
out many LN compartments may improve the likelihood
of responding to newly arising cutaneous metastases at dis-
tant sites. On the other hand, because control of lung tu-
mor outgrowth is unaffected by the presence or absence of
peripheral LN in albino mice, these data suggest that treat-
ment of tumors in highly vascularized organs may be best
achieved by immunizations that maximize the splenic T
cell response.
In summary, our results provide strong evidence for
nonoverlapping populations of LN- and spleen-resident
CD8  memory T cells that are differentially involved in
controlling tumors that grow in different body sites. Fur-
thermore, we demonstrated that these populations are dif-
ferentially induced depending on the route of immuniza-
tion with peptide-pulsed DCs. These data have significant
clinical implications, providing a basis for improvements inT
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tumor immunotherapy as well as an understanding of T cell
homing and regional immunity in general.
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